Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$4.63 -3.5%	$4.09	$2.49 ▼ $8.54	$433.18M	2.25	929,812 shs	2.10 million shs
GPCR Structure Therapeutics	$21.73 +0.5%	$23.26	$13.22 ▼ $47.48	$1.25B	-1.87	850,571 shs	749,888 shs
MLYS Mineralys Therapeutics	$13.48 -1.8%	$14.84	$8.24 ▼ $18.38	$878.56M	-0.17	530,943 shs	2.90 million shs
SYRE Spyre Therapeutics	$15.01 -0.5%	$14.98	$10.91 ▼ $40.26	$904.80M	2.72	601,918 shs	1.08 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	0.00%	+5.47%	+6.19%	+48.87%	-25.80%
GPCR Structure Therapeutics	0.00%	+0.23%	-11.49%	+3.23%	-52.32%
MLYS Mineralys Therapeutics	0.00%	-5.87%	-15.54%	-16.64%	+11.96%
SYRE Spyre Therapeutics	0.00%	-13.19%	0.00%	-21.08%	-37.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	1.7073 of 5 stars	3.5	3.0	0.0	0.8	0.6
GPCR Structure Therapeutics	1.6667 of 5 stars	3.5	2.0	0.0	1.7	0.6
MLYS Mineralys Therapeutics	2.8016 of 5 stars	3.4	3.0	2.0	4.2	0.0
SYRE Spyre Therapeutics	2.3541 of 5 stars	3.6	1.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	3.00	Buy	$18.83	306.77% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.50	252.05% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	139.24% Upside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	255.76% Upside

Current Analyst Ratings Breakdown

Latest CMPS, MLYS, GPCR, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/5/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
SYRE Spyre Therapeutics	$890K	1,016.63	N/A	N/A	$7.04 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.77	N/A	N/A	N/A	N/A	-77.46%	-41.06%	8/6/2025 (Estimated)

Latest CMPS, MLYS, GPCR, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
GPCR Structure Therapeutics	N/A	23.29	23.29
MLYS Mineralys Therapeutics	N/A	26.48	26.48
SYRE Spyre Therapeutics	N/A	8.06	8.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
GPCR Structure Therapeutics	91.78%
MLYS Mineralys Therapeutics	84.46%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
GPCR Structure Therapeutics	9.43%
MLYS Mineralys Therapeutics	25.56%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	56.54 million	Optionable

CMPS, MLYS, GPCR, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Analysts

June 22 at 4:21 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20 at 5:02 PM | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.7% - Here's Why

June 17, 2025 | marketbeat.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

June 16, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.5% - Time to Buy?

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

June 10, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - Here's What Happened

June 4, 2025 | marketbeat.com

122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

June 3, 2025 | marketbeat.com

Wellington Management Group LLP Has $37.35 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

June 1, 2025 | marketbeat.com

Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 31, 2025 | marketbeat.com

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know

May 30, 2025 | zacks.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Voloridge Investment Management LLC

May 29, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by Analysts

May 29, 2025 | marketbeat.com

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025 | prnewswire.com

BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 27, 2025 | marketbeat.com

Woodline Partners LP Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, MLYS, GPCR, and SYRE Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$4.63 -0.17 (-3.54%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.04 (-0.86%)

As of 06/20/2025 07:47 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Structure Therapeutics NASDAQ:GPCR

$21.73 +0.11 (+0.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$22.18 +0.45 (+2.09%)

As of 06/20/2025 07:59 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Mineralys Therapeutics NASDAQ:MLYS

$13.48 -0.25 (-1.82%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.48 -0.01 (-0.04%)

As of 06/20/2025 04:11 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Spyre Therapeutics NASDAQ:SYRE

$15.01 -0.07 (-0.46%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.01 0.00 (0.00%)

As of 06/20/2025 06:07 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time